Advicenne Announces Its Financial Calendar for 2022
27 Décembre 2021 - 2:41PM
Business Wire
Regulatory News:
Advicenne (Euronext: ADVIC) (Paris:ADVIC), a specialty
pharmaceutical company dedicated to developing and commercializing
innovative treatments for those suffering from rare renal diseases,
releases its financial Calendar for 2022.
Event
Date*
2021 Full-year financial results
March 31, 2022
Annual General Meeting
June 9, 2022
2022 H1 financial results
September 20, 2022
*: may be modified. After market close
About Advicenne
Advicenne (Euronext: ADVIC) is a pharmaceutical company founded
in 2007, specializing in the development of innovative treatments
in Nephrology. Its lead drug candidate is currently in late-stage
clinical trials for two kidney diseases: distal renal tubular
acidosis and cystinuria. ADV7103 has just received a positive CHMP
opinion for the treatment of dRTA. Headquartered in Paris,
Advicenne has been listed on the Euronext Paris stock exchange
since 2017 and was cross listed on the Euronext Brussels stock
exchange in 2019. For additional information see:
https://advicenne.com/
Forward-Looking Statements
This press release contains certain forward-looking statements
relating to the business of Advicenne, which shall not be
considered per se as historical facts. Such statements include
projections and estimates, and the hypotheses on which these are
based, as well as observations relating to operations, ongoing
projects, objectives, the development of products and their future
performance, and expectations regarding financial results.
In some cases, forward-looking statements can be identified by
words such as "could," "should," "may," "expects," "anticipates,"
"believes," "intends," "estimates," "aims," "targets" or similar
words. Although the management of Advicenne believes that these
forward-looking statements are reasonably made, investors should be
aware that they are subject to a number of known and unknown risks
and uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
these forward-looking statements. In particular, the expectations
of Advicenne could be affected by, among other things,
uncertainties involved in the placing on the market and
commercialization of Advicenne products or any other risks and
uncertainties developed or identified in any public documents filed
by Advicenne with the French Financial Markets Authority (Autorité
des marchés financiers (AMF)), including those listed in Chapter 4,
“Risk Factors,” of its universal registration document, filed with
the latter on December 22, 2020. Notwithstanding the compliance
with article 223-1 of the General Regulation of the AMF (the
information disclosed must be “accurate, precise and fairly
presented”), Advicenne disclaims any intention or obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211227005058/en/
Advicenne Didier Laurens, Chief Executive Officer +33
(0)4 66 05 54 20 Email: investors@advicenne.com
Consilium Strategic Communications Mary-Jane Elliott,
Ashley Tapp, Davide Salvi +44 (0)20 3709 5700 Email:
advicenne@consilium-comms.com
Ulysses Communication Media relations Bruno Arabian +33
(0)6 87 88 47 26 Email: advicenne@ulysse-communication.com